Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

Sonodynamic therapy (SDT) represents a promising modality that provides the possibility of
non-invasively eliminating solid tumors in a site-directed manner. In light of the complexity …

Effective treatments of neurodegenerative diseases require drugs to be actively transported
across the blood-brain barrier (BBB). However, nanoparticle drug carriers explored for this …

In this modern era, with the help of various advanced technologies, medical science has
overcome most of the health-related issues successfully. Though, some diseases still remain …

The blood–brain barrier (BBB) is a highly regulated and efficient barrier that provides a
sanctuary to the brain. It is designed to regulate brain homeostasis and to permit selective …

Drug delivery to the brain is hampered by the presence of the blood-brain barrier, which
excludes most molecules from freely diffusing into the brain, and tightly regulates the active …

Therapeutic gene silencing promises significant progress in pharmacotherapy, including
considerable expansion of the druggable target space and the possibility for treating orphan …